Sun Pharma Advanced Research Company DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.00×	1.00×	1.00×	1.00×	—
	0.99×	0.98×	1.02×	0.93×	—
	84.2%	84.5%	−467.5%	−548.8%	—
	1.50×	1.50×	0.17×	0.11×	—
	1.62×	1.62×	−1.55×	4.10×	1.62×
	201.8%	201.0%	125.5%	−230.9%	—
	277.4%	277.4%	751.5%	−121.3%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SPARC₹172.50

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health

₹ CrorePeersSTAR SHILPAMED SUPRIYA THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹5,598 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	—	1.00	1.00	1.00	1.00
Interest Burden (Pretax/EBIT) ×	—	0.93	1.02	0.98	0.99
EBIT Margin %	—	-548.79	-467.51	84.53	84.17
Asset Turnover ×	—	0.11	0.17	1.50	1.50
Financial Leverage (Assets/Equity) ×	1.62	4.10	-1.55	1.62	1.62
ROE (5-step product, year-end total equity) %	—	-230.91	125.47	201.03	201.80
ROE (owners' profit / average owners' equity) %	—	-121.28	751.54	277.35	277.35

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.